Navigation Links
Data on VIVUS' QNEXA to be Presented in Six Posters at The Obesity Society's Annual Meeting
Date:10/7/2010

ase Phentermine/Topiramate Improves Plasma Alanine Transaminase Concentrations (Abstract # 212894; Poster # 496-P)Presenter:

Ronette L. Kolotkin, PhDAuthors:

Kolotkin, Peterson, GaddeTitle:

Improvements in Quality of Life With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects (Abstract # 212896; Poster # 493-P)About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

VIVUS submitted a New Drug Application (NDA) to the FDA in December 2009 seeking approval of QNEXA for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity. An action date has been set for October 28, 2010.

About ObesityApproximately one-third of American adults (more than 72 million people) are obese, and many more are overweight with co-morbidities. Obesity is a chronic condition defined by having excess body fat. Obesity significantly increases the risk of developing many different diseases and health conditions, including type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, some cancers and osteoarthritis. According to a report in The Lancet in 2009, morbid obesity shortens life expectancy by approximately 10 years, an
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. ApoA-I Data Presented at European Society of Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... , Oct. 22, 2014 Research and ... Electronics Market by Material, by Application, Geography - Global ... their offering. Organic electronics, also called ... of material science which deals with small conductive molecules ... because small molecules and polymers are carbon based, made ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Calif., Oct. 5 MAP,Pharmaceuticals, Inc. announced today that ... of common stock at a price of $12.00 per,share. ... addition,MAP Pharmaceuticals has granted the underwriters a 30-day option ... over-allotments, if,any. Merrill Lynch & Co. and Morgan Stanley ...
... the, Latest Pre-FDA Multi-Hospital Study using the AppyScore Human Appendicitis ... Blood-based ... AspenBio Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... animals and humans, has been,invited to present at the Oppenheimer ...
... Oct. 5 Cerimon,Pharmaceuticals, Inc., today announced Paul ... at the 2007 BIO Investor Forum on,Thursday, October ... Palace Hotel in San,Francisco. The presentation will take ... Cerimon Pharmaceuticals Cerimon Pharmaceuticals, Inc. is a ...
Cached Biology Technology:MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 3
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
(Date:10/14/2014)... kind of stem cell that can become either a liver ... to a study published today in the journal Stem ... contradicts current theory on how organs arise from cell layers ... and future treatment for, liver cancer., Thanks to stem cells, ... made up of more than 200 cell types. The original, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... Faculty of Medicine & Dentistry at the University of ... neurons. This finding is significant because a specific type ... community as a potential treatment for MS and other ... fellow, Yohannes Haile, both from the Division of Neurology, ...
... they comprise most of the Earth,s total biodiversity and play key ... life in and on it, going. One of the global processes ... is currently unbalanced. Humans release more carbon into the atmosphere than ... Mighty Microbes Respond," is a free panel discussion set to take ...
... DALLAS May 6, 2011 Cancer researchers at ... of the telomerase enzyme, which is linked to the disease,s ... Cell , demonstrate that telomerase repairs chromosomes in one of ... normally or if the cell is under stress from enzyme ...
Cached Biology News:Discovery demonstrates potential MS therapy could kill brain cells 2UT Southwestern research reveals how cancer-driving enzyme works 2
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: